nodes	percent_of_prediction	percent_of_DWPC	metapath
Prasugrel—CYP3A4—Topotecan—ovarian cancer	0.0669	0.22	CbGbCtD
Prasugrel—CYP2B6—Doxorubicin—ovarian cancer	0.0581	0.191	CbGbCtD
Prasugrel—CYP2C9—Paclitaxel—ovarian cancer	0.057	0.187	CbGbCtD
Prasugrel—CYP3A4—Vinorelbine—ovarian cancer	0.0471	0.155	CbGbCtD
Prasugrel—CYP3A4—Paclitaxel—ovarian cancer	0.0331	0.109	CbGbCtD
Prasugrel—CYP3A4—Docetaxel—ovarian cancer	0.0239	0.0788	CbGbCtD
Prasugrel—CYP3A4—Doxorubicin—ovarian cancer	0.0179	0.0587	CbGbCtD
Prasugrel—P2RY12—epithelium—ovarian cancer	0.0113	0.116	CbGeAlD
Prasugrel—CES2—myometrium—ovarian cancer	0.0092	0.094	CbGeAlD
Prasugrel—CES2—uterine cervix—ovarian cancer	0.00716	0.0732	CbGeAlD
Prasugrel—CES2—decidua—ovarian cancer	0.00682	0.0697	CbGeAlD
Prasugrel—CES2—endometrium—ovarian cancer	0.00648	0.0662	CbGeAlD
Prasugrel—CES2—gonad—ovarian cancer	0.00601	0.0614	CbGeAlD
Prasugrel—CES2—uterus—ovarian cancer	0.00597	0.061	CbGeAlD
Prasugrel—CES2—female reproductive system—ovarian cancer	0.00537	0.0548	CbGeAlD
Prasugrel—CES2—bone marrow—ovarian cancer	0.00507	0.0517	CbGeAlD
Prasugrel—CES2—female gonad—ovarian cancer	0.00488	0.0499	CbGeAlD
Prasugrel—Clopidogrel—ABCB1—ovarian cancer	0.00486	1	CrCbGaD
Prasugrel—CES2—vagina—ovarian cancer	0.00485	0.0496	CbGeAlD
Prasugrel—CES2—testis—ovarian cancer	0.00433	0.0442	CbGeAlD
Prasugrel—Gingival bleeding—Epirubicin—ovarian cancer	0.00334	0.0063	CcSEcCtD
Prasugrel—CES2—lymph node—ovarian cancer	0.00314	0.0321	CbGeAlD
Prasugrel—Gingival bleeding—Doxorubicin—ovarian cancer	0.00309	0.00583	CcSEcCtD
Prasugrel—Epistaxis—Topotecan—ovarian cancer	0.00304	0.00574	CcSEcCtD
Prasugrel—Neoplasm—Paclitaxel—ovarian cancer	0.003	0.00566	CcSEcCtD
Prasugrel—Haemoglobin—Topotecan—ovarian cancer	0.00291	0.00549	CcSEcCtD
Prasugrel—Haemorrhage—Topotecan—ovarian cancer	0.0029	0.00546	CcSEcCtD
Prasugrel—Haemoglobin—Melphalan—ovarian cancer	0.00285	0.00537	CcSEcCtD
Prasugrel—Haemorrhage—Melphalan—ovarian cancer	0.00284	0.00535	CcSEcCtD
Prasugrel—Urinary tract disorder—Melphalan—ovarian cancer	0.0028	0.00528	CcSEcCtD
Prasugrel—Urethral disorder—Melphalan—ovarian cancer	0.00278	0.00524	CcSEcCtD
Prasugrel—Hyperlipidaemia—Epirubicin—ovarian cancer	0.00263	0.00496	CcSEcCtD
Prasugrel—Angiopathy—Topotecan—ovarian cancer	0.00263	0.00496	CcSEcCtD
Prasugrel—Anaemia—Chlorambucil—ovarian cancer	0.00262	0.00494	CcSEcCtD
Prasugrel—Immune system disorder—Topotecan—ovarian cancer	0.00262	0.00493	CcSEcCtD
Prasugrel—Mediastinal disorder—Topotecan—ovarian cancer	0.00261	0.00492	CcSEcCtD
Prasugrel—Angioedema—Chlorambucil—ovarian cancer	0.00259	0.00488	CcSEcCtD
Prasugrel—Haemoptysis—Epirubicin—ovarian cancer	0.00256	0.00483	CcSEcCtD
Prasugrel—Immune system disorder—Melphalan—ovarian cancer	0.00256	0.00483	CcSEcCtD
Prasugrel—Mediastinal disorder—Melphalan—ovarian cancer	0.00256	0.00482	CcSEcCtD
Prasugrel—Neoplasm—Docetaxel—ovarian cancer	0.00254	0.0048	CcSEcCtD
Prasugrel—Atrial fibrillation—Paclitaxel—ovarian cancer	0.00254	0.00479	CcSEcCtD
Prasugrel—Leukopenia—Chlorambucil—ovarian cancer	0.00254	0.00478	CcSEcCtD
Prasugrel—ALB—testis—ovarian cancer	0.00248	0.0253	CbGeAlD
Prasugrel—Cerebrovascular accident—Paclitaxel—ovarian cancer	0.00246	0.00464	CcSEcCtD
Prasugrel—Back pain—Topotecan—ovarian cancer	0.00244	0.0046	CcSEcCtD
Prasugrel—Hyperlipidaemia—Doxorubicin—ovarian cancer	0.00244	0.00459	CcSEcCtD
Prasugrel—Pain in extremity—Paclitaxel—ovarian cancer	0.00241	0.00454	CcSEcCtD
Prasugrel—Haemoptysis—Doxorubicin—ovarian cancer	0.00237	0.00447	CcSEcCtD
Prasugrel—Anaemia—Topotecan—ovarian cancer	0.00233	0.00439	CcSEcCtD
Prasugrel—Angioedema—Topotecan—ovarian cancer	0.0023	0.00434	CcSEcCtD
Prasugrel—Anaemia—Melphalan—ovarian cancer	0.00228	0.0043	CcSEcCtD
Prasugrel—Thrombocytopenia—Chlorambucil—ovarian cancer	0.00226	0.00427	CcSEcCtD
Prasugrel—Leukopenia—Topotecan—ovarian cancer	0.00226	0.00426	CcSEcCtD
Prasugrel—Angiopathy—Vinorelbine—ovarian cancer	0.00225	0.00424	CcSEcCtD
Prasugrel—Immune system disorder—Vinorelbine—ovarian cancer	0.00224	0.00422	CcSEcCtD
Prasugrel—CYP2C19—vagina—ovarian cancer	0.00224	0.0228	CbGeAlD
Prasugrel—Mediastinal disorder—Vinorelbine—ovarian cancer	0.00223	0.00421	CcSEcCtD
Prasugrel—Neoplasm malignant—Epirubicin—ovarian cancer	0.00222	0.00419	CcSEcCtD
Prasugrel—Leukopenia—Melphalan—ovarian cancer	0.00221	0.00417	CcSEcCtD
Prasugrel—Cough—Topotecan—ovarian cancer	0.0022	0.00415	CcSEcCtD
Prasugrel—CYP2B6—gonad—ovarian cancer	0.00217	0.0221	CbGeAlD
Prasugrel—Atrial fibrillation—Docetaxel—ovarian cancer	0.00215	0.00406	CcSEcCtD
Prasugrel—Cough—Melphalan—ovarian cancer	0.00215	0.00406	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.00213	0.00402	CcSEcCtD
Prasugrel—Rectal haemorrhage—Epirubicin—ovarian cancer	0.0021	0.00396	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.00209	0.00394	CcSEcCtD
Prasugrel—Back pain—Vinorelbine—ovarian cancer	0.00209	0.00393	CcSEcCtD
Prasugrel—Anaphylactic shock—Topotecan—ovarian cancer	0.00206	0.00388	CcSEcCtD
Prasugrel—Neoplasm malignant—Doxorubicin—ovarian cancer	0.00206	0.00388	CcSEcCtD
Prasugrel—Pain in extremity—Docetaxel—ovarian cancer	0.00204	0.00385	CcSEcCtD
Prasugrel—Gastrointestinal haemorrhage—Docetaxel—ovarian cancer	0.00204	0.00385	CcSEcCtD
Prasugrel—Anaphylactic shock—Melphalan—ovarian cancer	0.00201	0.0038	CcSEcCtD
Prasugrel—Thrombocytopenia—Topotecan—ovarian cancer	0.00201	0.0038	CcSEcCtD
Prasugrel—Skin disorder—Topotecan—ovarian cancer	0.002	0.00377	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.002	0.00376	CcSEcCtD
Prasugrel—Anaemia—Vinorelbine—ovarian cancer	0.00199	0.00376	CcSEcCtD
Prasugrel—Fatigue—Chlorambucil—ovarian cancer	0.00199	0.00376	CcSEcCtD
Prasugrel—Thrombocytopenia—Melphalan—ovarian cancer	0.00197	0.00372	CcSEcCtD
Prasugrel—Angioedema—Vinorelbine—ovarian cancer	0.00197	0.00372	CcSEcCtD
Prasugrel—Skin disorder—Melphalan—ovarian cancer	0.00196	0.00369	CcSEcCtD
Prasugrel—Rectal haemorrhage—Doxorubicin—ovarian cancer	0.00194	0.00366	CcSEcCtD
Prasugrel—CYP2B6—female reproductive system—ovarian cancer	0.00194	0.0198	CbGeAlD
Prasugrel—Leukopenia—Vinorelbine—ovarian cancer	0.00193	0.00364	CcSEcCtD
Prasugrel—CYP2C9—female reproductive system—ovarian cancer	0.00192	0.0196	CbGeAlD
Prasugrel—Hypotension—Melphalan—ovarian cancer	0.00188	0.00355	CcSEcCtD
Prasugrel—Cough—Vinorelbine—ovarian cancer	0.00188	0.00355	CcSEcCtD
Prasugrel—Hypertension—Vinorelbine—ovarian cancer	0.00186	0.00351	CcSEcCtD
Prasugrel—Dyspnoea—Topotecan—ovarian cancer	0.00183	0.00346	CcSEcCtD
Prasugrel—Body temperature increased—Chlorambucil—ovarian cancer	0.00183	0.00345	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.00182	0.00344	CcSEcCtD
Prasugrel—ALB—lymph node—ovarian cancer	0.0018	0.0184	CbGeAlD
Prasugrel—Dyspnoea—Melphalan—ovarian cancer	0.0018	0.00339	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00178	0.00335	CcSEcCtD
Prasugrel—Fatigue—Topotecan—ovarian cancer	0.00177	0.00335	CcSEcCtD
Prasugrel—Haematuria—Paclitaxel—ovarian cancer	0.00177	0.00334	CcSEcCtD
Prasugrel—Anaphylactic shock—Vinorelbine—ovarian cancer	0.00176	0.00332	CcSEcCtD
Prasugrel—CYP2B6—vagina—ovarian cancer	0.00175	0.0179	CbGeAlD
Prasugrel—Epistaxis—Paclitaxel—ovarian cancer	0.00175	0.0033	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00174	0.00328	CcSEcCtD
Prasugrel—Fatigue—Melphalan—ovarian cancer	0.00174	0.00328	CcSEcCtD
Prasugrel—Thrombocytopenia—Vinorelbine—ovarian cancer	0.00172	0.00325	CcSEcCtD
Prasugrel—Neoplasm—Epirubicin—ovarian cancer	0.00172	0.00323	CcSEcCtD
Prasugrel—Ecchymosis—Epirubicin—ovarian cancer	0.00172	0.00323	CcSEcCtD
Prasugrel—Skin disorder—Vinorelbine—ovarian cancer	0.00171	0.00322	CcSEcCtD
Prasugrel—Hypersensitivity—Chlorambucil—ovarian cancer	0.0017	0.00321	CcSEcCtD
Prasugrel—Bradycardia—Paclitaxel—ovarian cancer	0.0017	0.0032	CcSEcCtD
Prasugrel—Haemoglobin—Paclitaxel—ovarian cancer	0.00167	0.00316	CcSEcCtD
Prasugrel—Haemorrhage—Paclitaxel—ovarian cancer	0.00167	0.00314	CcSEcCtD
Prasugrel—Asthenia—Chlorambucil—ovarian cancer	0.00166	0.00313	CcSEcCtD
Prasugrel—Urinary tract disorder—Paclitaxel—ovarian cancer	0.00165	0.0031	CcSEcCtD
Prasugrel—Hypotension—Vinorelbine—ovarian cancer	0.00164	0.0031	CcSEcCtD
Prasugrel—Oedema peripheral—Paclitaxel—ovarian cancer	0.00164	0.0031	CcSEcCtD
Prasugrel—Urethral disorder—Paclitaxel—ovarian cancer	0.00163	0.00308	CcSEcCtD
Prasugrel—Body temperature increased—Topotecan—ovarian cancer	0.00163	0.00307	CcSEcCtD
Prasugrel—Neoplasm—Doxorubicin—ovarian cancer	0.00159	0.00299	CcSEcCtD
Prasugrel—Ecchymosis—Doxorubicin—ovarian cancer	0.00159	0.00299	CcSEcCtD
Prasugrel—Diarrhoea—Chlorambucil—ovarian cancer	0.00158	0.00298	CcSEcCtD
Prasugrel—Dyspnoea—Vinorelbine—ovarian cancer	0.00157	0.00296	CcSEcCtD
Prasugrel—CYP2B6—testis—ovarian cancer	0.00156	0.016	CbGeAlD
Prasugrel—Eye disorder—Paclitaxel—ovarian cancer	0.00156	0.00294	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00152	0.00287	CcSEcCtD
Prasugrel—Fatigue—Vinorelbine—ovarian cancer	0.00152	0.00286	CcSEcCtD
Prasugrel—Hypersensitivity—Topotecan—ovarian cancer	0.00152	0.00286	CcSEcCtD
Prasugrel—Angiopathy—Paclitaxel—ovarian cancer	0.00151	0.00285	CcSEcCtD
Prasugrel—Immune system disorder—Paclitaxel—ovarian cancer	0.00151	0.00284	CcSEcCtD
Prasugrel—Mediastinal disorder—Paclitaxel—ovarian cancer	0.0015	0.00283	CcSEcCtD
Prasugrel—Hypersensitivity—Melphalan—ovarian cancer	0.00148	0.0028	CcSEcCtD
Prasugrel—Epistaxis—Docetaxel—ovarian cancer	0.00148	0.0028	CcSEcCtD
Prasugrel—Asthenia—Topotecan—ovarian cancer	0.00148	0.00278	CcSEcCtD
Prasugrel—CYP3A4—female reproductive system—ovarian cancer	0.00146	0.0149	CbGeAlD
Prasugrel—Asthenia—Melphalan—ovarian cancer	0.00145	0.00273	CcSEcCtD
Prasugrel—Haemoglobin—Docetaxel—ovarian cancer	0.00142	0.00268	CcSEcCtD
Prasugrel—Haemorrhage—Docetaxel—ovarian cancer	0.00141	0.00266	CcSEcCtD
Prasugrel—Diarrhoea—Topotecan—ovarian cancer	0.00141	0.00265	CcSEcCtD
Prasugrel—Cerebrovascular accident—Epirubicin—ovarian cancer	0.00141	0.00265	CcSEcCtD
Prasugrel—Back pain—Paclitaxel—ovarian cancer	0.0014	0.00265	CcSEcCtD
Prasugrel—Urinary tract disorder—Docetaxel—ovarian cancer	0.00139	0.00263	CcSEcCtD
Prasugrel—Body temperature increased—Vinorelbine—ovarian cancer	0.00139	0.00262	CcSEcCtD
Prasugrel—Oedema peripheral—Docetaxel—ovarian cancer	0.00139	0.00262	CcSEcCtD
Prasugrel—Urethral disorder—Docetaxel—ovarian cancer	0.00138	0.00261	CcSEcCtD
Prasugrel—Diarrhoea—Melphalan—ovarian cancer	0.00138	0.0026	CcSEcCtD
Prasugrel—Pain in extremity—Epirubicin—ovarian cancer	0.00138	0.0026	CcSEcCtD
Prasugrel—Gastrointestinal haemorrhage—Epirubicin—ovarian cancer	0.00138	0.0026	CcSEcCtD
Prasugrel—Nausea—Chlorambucil—ovarian cancer	0.00137	0.00259	CcSEcCtD
Prasugrel—Dizziness—Topotecan—ovarian cancer	0.00136	0.00257	CcSEcCtD
Prasugrel—Anaemia—Paclitaxel—ovarian cancer	0.00134	0.00253	CcSEcCtD
Prasugrel—Angioedema—Paclitaxel—ovarian cancer	0.00133	0.0025	CcSEcCtD
Prasugrel—Eye disorder—Docetaxel—ovarian cancer	0.00132	0.00249	CcSEcCtD
Prasugrel—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.0013	0.00245	CcSEcCtD
Prasugrel—Leukopenia—Paclitaxel—ovarian cancer	0.0013	0.00245	CcSEcCtD
Prasugrel—Rash—Topotecan—ovarian cancer	0.0013	0.00245	CcSEcCtD
Prasugrel—Hypersensitivity—Vinorelbine—ovarian cancer	0.0013	0.00245	CcSEcCtD
Prasugrel—Dermatitis—Topotecan—ovarian cancer	0.0013	0.00244	CcSEcCtD
Prasugrel—Headache—Topotecan—ovarian cancer	0.00129	0.00243	CcSEcCtD
Prasugrel—Angiopathy—Docetaxel—ovarian cancer	0.00128	0.00242	CcSEcCtD
Prasugrel—Immune system disorder—Docetaxel—ovarian cancer	0.00128	0.00241	CcSEcCtD
Prasugrel—Pain in extremity—Doxorubicin—ovarian cancer	0.00127	0.0024	CcSEcCtD
Prasugrel—Gastrointestinal haemorrhage—Doxorubicin—ovarian cancer	0.00127	0.0024	CcSEcCtD
Prasugrel—Mediastinal disorder—Docetaxel—ovarian cancer	0.00127	0.0024	CcSEcCtD
Prasugrel—Rash—Melphalan—ovarian cancer	0.00127	0.0024	CcSEcCtD
Prasugrel—Dermatitis—Melphalan—ovarian cancer	0.00127	0.00239	CcSEcCtD
Prasugrel—Cough—Paclitaxel—ovarian cancer	0.00127	0.00239	CcSEcCtD
Prasugrel—Asthenia—Vinorelbine—ovarian cancer	0.00126	0.00238	CcSEcCtD
Prasugrel—Hypertension—Paclitaxel—ovarian cancer	0.00125	0.00236	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.00123	0.00231	CcSEcCtD
Prasugrel—Nausea—Topotecan—ovarian cancer	0.00122	0.0023	CcSEcCtD
Prasugrel—Diarrhoea—Vinorelbine—ovarian cancer	0.0012	0.00227	CcSEcCtD
Prasugrel—Nausea—Melphalan—ovarian cancer	0.0012	0.00226	CcSEcCtD
Prasugrel—Back pain—Docetaxel—ovarian cancer	0.00119	0.00224	CcSEcCtD
Prasugrel—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00118	0.00223	CcSEcCtD
Prasugrel—Dizziness—Vinorelbine—ovarian cancer	0.00116	0.00219	CcSEcCtD
Prasugrel—Thrombocytopenia—Paclitaxel—ovarian cancer	0.00116	0.00219	CcSEcCtD
Prasugrel—Skin disorder—Paclitaxel—ovarian cancer	0.00115	0.00217	CcSEcCtD
Prasugrel—Anaemia—Docetaxel—ovarian cancer	0.00114	0.00214	CcSEcCtD
Prasugrel—Rash—Vinorelbine—ovarian cancer	0.00111	0.00209	CcSEcCtD
Prasugrel—Dermatitis—Vinorelbine—ovarian cancer	0.00111	0.00209	CcSEcCtD
Prasugrel—Hypotension—Paclitaxel—ovarian cancer	0.00111	0.00209	CcSEcCtD
Prasugrel—Headache—Vinorelbine—ovarian cancer	0.0011	0.00208	CcSEcCtD
Prasugrel—Leukopenia—Docetaxel—ovarian cancer	0.0011	0.00208	CcSEcCtD
Prasugrel—Cough—Docetaxel—ovarian cancer	0.00107	0.00202	CcSEcCtD
Prasugrel—Hypertension—Docetaxel—ovarian cancer	0.00106	0.002	CcSEcCtD
Prasugrel—Dyspnoea—Paclitaxel—ovarian cancer	0.00106	0.00199	CcSEcCtD
Prasugrel—Nausea—Vinorelbine—ovarian cancer	0.00105	0.00197	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00104	0.00196	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00102	0.00193	CcSEcCtD
Prasugrel—Fatigue—Paclitaxel—ovarian cancer	0.00102	0.00192	CcSEcCtD
Prasugrel—Haematuria—Epirubicin—ovarian cancer	0.00101	0.00191	CcSEcCtD
Prasugrel—Anaphylactic shock—Docetaxel—ovarian cancer	0.001	0.00189	CcSEcCtD
Prasugrel—Epistaxis—Epirubicin—ovarian cancer	0.001	0.00189	CcSEcCtD
Prasugrel—Thrombocytopenia—Docetaxel—ovarian cancer	0.000983	0.00185	CcSEcCtD
Prasugrel—Skin disorder—Docetaxel—ovarian cancer	0.000975	0.00184	CcSEcCtD
Prasugrel—Bradycardia—Epirubicin—ovarian cancer	0.00097	0.00183	CcSEcCtD
Prasugrel—Haemoglobin—Epirubicin—ovarian cancer	0.000958	0.00181	CcSEcCtD
Prasugrel—Haemorrhage—Epirubicin—ovarian cancer	0.000953	0.0018	CcSEcCtD
Prasugrel—Urinary tract disorder—Epirubicin—ovarian cancer	0.000941	0.00177	CcSEcCtD
Prasugrel—Oedema peripheral—Epirubicin—ovarian cancer	0.000939	0.00177	CcSEcCtD
Prasugrel—Hypotension—Docetaxel—ovarian cancer	0.000938	0.00177	CcSEcCtD
Prasugrel—Haematuria—Doxorubicin—ovarian cancer	0.000936	0.00177	CcSEcCtD
Prasugrel—Body temperature increased—Paclitaxel—ovarian cancer	0.000936	0.00176	CcSEcCtD
Prasugrel—Urethral disorder—Epirubicin—ovarian cancer	0.000934	0.00176	CcSEcCtD
Prasugrel—Epistaxis—Doxorubicin—ovarian cancer	0.000926	0.00175	CcSEcCtD
Prasugrel—Bradycardia—Doxorubicin—ovarian cancer	0.000897	0.00169	CcSEcCtD
Prasugrel—Dyspnoea—Docetaxel—ovarian cancer	0.000895	0.00169	CcSEcCtD
Prasugrel—Eye disorder—Epirubicin—ovarian cancer	0.00089	0.00168	CcSEcCtD
Prasugrel—Haemoglobin—Doxorubicin—ovarian cancer	0.000886	0.00167	CcSEcCtD
Prasugrel—Haemorrhage—Doxorubicin—ovarian cancer	0.000882	0.00166	CcSEcCtD
Prasugrel—Hypersensitivity—Paclitaxel—ovarian cancer	0.000872	0.00164	CcSEcCtD
Prasugrel—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000871	0.00164	CcSEcCtD
Prasugrel—Oedema peripheral—Doxorubicin—ovarian cancer	0.000868	0.00164	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000866	0.00163	CcSEcCtD
Prasugrel—Fatigue—Docetaxel—ovarian cancer	0.000865	0.00163	CcSEcCtD
Prasugrel—Angiopathy—Epirubicin—ovarian cancer	0.000864	0.00163	CcSEcCtD
Prasugrel—Urethral disorder—Doxorubicin—ovarian cancer	0.000864	0.00163	CcSEcCtD
Prasugrel—Immune system disorder—Epirubicin—ovarian cancer	0.000861	0.00162	CcSEcCtD
Prasugrel—Mediastinal disorder—Epirubicin—ovarian cancer	0.000859	0.00162	CcSEcCtD
Prasugrel—Asthenia—Paclitaxel—ovarian cancer	0.000849	0.0016	CcSEcCtD
Prasugrel—Eye disorder—Doxorubicin—ovarian cancer	0.000824	0.00155	CcSEcCtD
Prasugrel—Diarrhoea—Paclitaxel—ovarian cancer	0.00081	0.00153	CcSEcCtD
Prasugrel—Back pain—Epirubicin—ovarian cancer	0.000802	0.00151	CcSEcCtD
Prasugrel—Angiopathy—Doxorubicin—ovarian cancer	0.0008	0.00151	CcSEcCtD
Prasugrel—Immune system disorder—Doxorubicin—ovarian cancer	0.000796	0.0015	CcSEcCtD
Prasugrel—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000795	0.0015	CcSEcCtD
Prasugrel—Body temperature increased—Docetaxel—ovarian cancer	0.000793	0.0015	CcSEcCtD
Prasugrel—Dizziness—Paclitaxel—ovarian cancer	0.000783	0.00148	CcSEcCtD
Prasugrel—Anaemia—Epirubicin—ovarian cancer	0.000767	0.00145	CcSEcCtD
Prasugrel—Rash—Paclitaxel—ovarian cancer	0.000747	0.00141	CcSEcCtD
Prasugrel—Dermatitis—Paclitaxel—ovarian cancer	0.000746	0.00141	CcSEcCtD
Prasugrel—Leukopenia—Epirubicin—ovarian cancer	0.000742	0.0014	CcSEcCtD
Prasugrel—Back pain—Doxorubicin—ovarian cancer	0.000742	0.0014	CcSEcCtD
Prasugrel—Headache—Paclitaxel—ovarian cancer	0.000742	0.0014	CcSEcCtD
Prasugrel—Hypersensitivity—Docetaxel—ovarian cancer	0.000739	0.00139	CcSEcCtD
Prasugrel—Cough—Epirubicin—ovarian cancer	0.000724	0.00136	CcSEcCtD
Prasugrel—Asthenia—Docetaxel—ovarian cancer	0.00072	0.00136	CcSEcCtD
Prasugrel—Hypertension—Epirubicin—ovarian cancer	0.000716	0.00135	CcSEcCtD
Prasugrel—Anaemia—Doxorubicin—ovarian cancer	0.000709	0.00134	CcSEcCtD
Prasugrel—Nausea—Paclitaxel—ovarian cancer	0.000703	0.00133	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000701	0.00132	CcSEcCtD
Prasugrel—Leukopenia—Doxorubicin—ovarian cancer	0.000687	0.0013	CcSEcCtD
Prasugrel—Diarrhoea—Docetaxel—ovarian cancer	0.000687	0.00129	CcSEcCtD
Prasugrel—Anaphylactic shock—Epirubicin—ovarian cancer	0.000677	0.00128	CcSEcCtD
Prasugrel—Cough—Doxorubicin—ovarian cancer	0.00067	0.00126	CcSEcCtD
Prasugrel—Dizziness—Docetaxel—ovarian cancer	0.000664	0.00125	CcSEcCtD
Prasugrel—Thrombocytopenia—Epirubicin—ovarian cancer	0.000663	0.00125	CcSEcCtD
Prasugrel—Hypertension—Doxorubicin—ovarian cancer	0.000663	0.00125	CcSEcCtD
Prasugrel—Skin disorder—Epirubicin—ovarian cancer	0.000657	0.00124	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000649	0.00122	CcSEcCtD
Prasugrel—Rash—Docetaxel—ovarian cancer	0.000633	0.00119	CcSEcCtD
Prasugrel—Hypotension—Epirubicin—ovarian cancer	0.000633	0.00119	CcSEcCtD
Prasugrel—Dermatitis—Docetaxel—ovarian cancer	0.000632	0.00119	CcSEcCtD
Prasugrel—Headache—Docetaxel—ovarian cancer	0.000629	0.00119	CcSEcCtD
Prasugrel—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000626	0.00118	CcSEcCtD
Prasugrel—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000613	0.00116	CcSEcCtD
Prasugrel—Skin disorder—Doxorubicin—ovarian cancer	0.000608	0.00115	CcSEcCtD
Prasugrel—Dyspnoea—Epirubicin—ovarian cancer	0.000603	0.00114	CcSEcCtD
Prasugrel—Nausea—Docetaxel—ovarian cancer	0.000596	0.00112	CcSEcCtD
Prasugrel—Hypotension—Doxorubicin—ovarian cancer	0.000585	0.0011	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000584	0.0011	CcSEcCtD
Prasugrel—Fatigue—Epirubicin—ovarian cancer	0.000584	0.0011	CcSEcCtD
Prasugrel—Dyspnoea—Doxorubicin—ovarian cancer	0.000558	0.00105	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000541	0.00102	CcSEcCtD
Prasugrel—Fatigue—Doxorubicin—ovarian cancer	0.00054	0.00102	CcSEcCtD
Prasugrel—Body temperature increased—Epirubicin—ovarian cancer	0.000535	0.00101	CcSEcCtD
Prasugrel—Hypersensitivity—Epirubicin—ovarian cancer	0.000499	0.00094	CcSEcCtD
Prasugrel—Body temperature increased—Doxorubicin—ovarian cancer	0.000495	0.000934	CcSEcCtD
Prasugrel—Asthenia—Epirubicin—ovarian cancer	0.000486	0.000916	CcSEcCtD
Prasugrel—Diarrhoea—Epirubicin—ovarian cancer	0.000463	0.000873	CcSEcCtD
Prasugrel—Hypersensitivity—Doxorubicin—ovarian cancer	0.000461	0.00087	CcSEcCtD
Prasugrel—Asthenia—Doxorubicin—ovarian cancer	0.000449	0.000847	CcSEcCtD
Prasugrel—Dizziness—Epirubicin—ovarian cancer	0.000448	0.000844	CcSEcCtD
Prasugrel—Diarrhoea—Doxorubicin—ovarian cancer	0.000429	0.000808	CcSEcCtD
Prasugrel—Rash—Epirubicin—ovarian cancer	0.000427	0.000805	CcSEcCtD
Prasugrel—Dermatitis—Epirubicin—ovarian cancer	0.000426	0.000804	CcSEcCtD
Prasugrel—Headache—Epirubicin—ovarian cancer	0.000424	0.0008	CcSEcCtD
Prasugrel—Dizziness—Doxorubicin—ovarian cancer	0.000414	0.000781	CcSEcCtD
Prasugrel—Nausea—Epirubicin—ovarian cancer	0.000402	0.000758	CcSEcCtD
Prasugrel—Rash—Doxorubicin—ovarian cancer	0.000395	0.000745	CcSEcCtD
Prasugrel—Dermatitis—Doxorubicin—ovarian cancer	0.000395	0.000744	CcSEcCtD
Prasugrel—Headache—Doxorubicin—ovarian cancer	0.000392	0.00074	CcSEcCtD
Prasugrel—Nausea—Doxorubicin—ovarian cancer	0.000372	0.000701	CcSEcCtD
Prasugrel—ALB—Folate Metabolism—IL2—ovarian cancer	0.000127	0.00202	CbGpPWpGaD
Prasugrel—CYP2C19—Biological oxidations—CYP1B1—ovarian cancer	0.000127	0.00201	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—PIK3CD—ovarian cancer	0.000125	0.00199	CbGpPWpGaD
Prasugrel—CYP2C19—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000125	0.00199	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—HDAC6—ovarian cancer	0.000124	0.00197	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—PPP2R1A—ovarian cancer	0.000122	0.00194	CbGpPWpGaD
Prasugrel—P2RY12—GPCR ligand binding—CXCL8—ovarian cancer	0.000117	0.00186	CbGpPWpGaD
Prasugrel—CYP2C9—Biological oxidations—CYP1B1—ovarian cancer	0.000115	0.00184	CbGpPWpGaD
Prasugrel—CYP2C9—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000114	0.00181	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—AQP3—ovarian cancer	0.00011	0.00175	CbGpPWpGaD
Prasugrel—ALB—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	0.000109	0.00174	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—YAP1—ovarian cancer	0.000109	0.00174	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—PIK3CB—ovarian cancer	0.000109	0.00173	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000109	0.00173	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—XIAP—ovarian cancer	0.000107	0.0017	CbGpPWpGaD
Prasugrel—ALB—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	0.000106	0.00168	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—ATP7B—ovarian cancer	0.000105	0.00168	CbGpPWpGaD
Prasugrel—P2RY12—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	0.000105	0.00167	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—SMARCA4—ovarian cancer	0.000104	0.00166	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—SOD1—ovarian cancer	0.000103	0.00164	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—NME2—ovarian cancer	0.000102	0.00162	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—EREG—ovarian cancer	0.000102	0.00162	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—IL2—ovarian cancer	0.0001	0.00159	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	9.75e-05	0.00155	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PGR—ovarian cancer	9.55e-05	0.00152	CbGpPWpGaD
Prasugrel—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—ovarian cancer	9.5e-05	0.00151	CbGpPWpGaD
Prasugrel—ALB—Platelet degranulation—VEGFA—ovarian cancer	9.23e-05	0.00147	CbGpPWpGaD
Prasugrel—ALB—Vitamin B12 Metabolism—IL6—ovarian cancer	9.15e-05	0.00146	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—PIK3CG—ovarian cancer	8.98e-05	0.00143	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	8.89e-05	0.00142	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PARP1—ovarian cancer	8.88e-05	0.00141	CbGpPWpGaD
Prasugrel—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—ovarian cancer	8.79e-05	0.0014	CbGpPWpGaD
Prasugrel—ALB—Metabolism—NME2—ovarian cancer	8.59e-05	0.00137	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—VEGFA—ovarian cancer	8.5e-05	0.00135	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—IL6ST—ovarian cancer	8.49e-05	0.00135	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—NRAS—ovarian cancer	8.4e-05	0.00134	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—TUBB3—ovarian cancer	8.33e-05	0.00133	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—PIK3CG—ovarian cancer	8.16e-05	0.0013	CbGpPWpGaD
Prasugrel—ALB—Folate Metabolism—TP53—ovarian cancer	8.13e-05	0.00129	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—MAPK3—ovarian cancer	8.04e-05	0.00128	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—PIK3CD—ovarian cancer	7.9e-05	0.00126	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—NME2—ovarian cancer	7.71e-05	0.00123	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—MAPK1—ovarian cancer	7.65e-05	0.00122	CbGpPWpGaD
Prasugrel—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	7.61e-05	0.00121	CbGpPWpGaD
Prasugrel—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	7.5e-05	0.00119	CbGpPWpGaD
Prasugrel—ALB—Folate Metabolism—IL6—ovarian cancer	7.45e-05	0.00118	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—SPARC—ovarian cancer	7.29e-05	0.00116	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	7.29e-05	0.00116	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—KRAS—ovarian cancer	7.23e-05	0.00115	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PPP2R1A—ovarian cancer	7.2e-05	0.00115	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—PIK3CD—ovarian cancer	7.17e-05	0.00114	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—NME2—ovarian cancer	7.03e-05	0.00112	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—PIK3CB—ovarian cancer	6.88e-05	0.0011	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—PIK3CG—ovarian cancer	6.85e-05	0.00109	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—PIK3CA—ovarian cancer	6.64e-05	0.00106	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—CXCL8—ovarian cancer	6.61e-05	0.00105	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—CYTB—ovarian cancer	6.58e-05	0.00105	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	6.54e-05	0.00104	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—TP53—ovarian cancer	6.42e-05	0.00102	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—IL2—ovarian cancer	6.32e-05	0.00101	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—PIK3CB—ovarian cancer	6.25e-05	0.000995	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—HRAS—ovarian cancer	6.14e-05	0.000978	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—PIK3CD—ovarian cancer	6.02e-05	0.000958	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—CXCL8—ovarian cancer	6.01e-05	0.000956	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	5.97e-05	0.000949	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	5.94e-05	0.000945	CbGpPWpGaD
Prasugrel—ALB—Selenium Micronutrient Network—IL6—ovarian cancer	5.91e-05	0.000941	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PPP1CC—ovarian cancer	5.75e-05	0.000915	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—BRIP1—ovarian cancer	5.75e-05	0.000915	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—IL2—ovarian cancer	5.74e-05	0.000914	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—TERT—ovarian cancer	5.72e-05	0.00091	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	5.56e-05	0.000884	CbGpPWpGaD
Prasugrel—ALB—Metabolism—CYTB—ovarian cancer	5.54e-05	0.000881	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—AKT1—ovarian cancer	5.42e-05	0.000863	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	5.41e-05	0.000861	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	5.37e-05	0.000854	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	5.33e-05	0.000849	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—SOD1—ovarian cancer	5.3e-05	0.000843	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CAV1—ovarian cancer	5.29e-05	0.000842	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—PPP2R1A—ovarian cancer	5.27e-05	0.000839	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—PIK3CB—ovarian cancer	5.25e-05	0.000835	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—ESR1—ovarian cancer	5.1e-05	0.000811	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—IL6ST—ovarian cancer	5.02e-05	0.000798	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—CYTB—ovarian cancer	4.97e-05	0.000791	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	4.86e-05	0.000774	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.86e-05	0.000773	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PPP1CC—ovarian cancer	4.84e-05	0.00077	CbGpPWpGaD
Prasugrel—ALB—Metabolism—BRIP1—ovarian cancer	4.84e-05	0.00077	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PIK3CG—ovarian cancer	4.82e-05	0.000767	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—APC—ovarian cancer	4.82e-05	0.000767	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—NRAS—ovarian cancer	4.82e-05	0.000767	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—IL2—ovarian cancer	4.82e-05	0.000767	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—NME2—ovarian cancer	4.64e-05	0.000738	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—MAPK3—ovarian cancer	4.62e-05	0.000734	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—CYTB—ovarian cancer	4.53e-05	0.000721	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.43e-05	0.000705	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—MAPK1—ovarian cancer	4.39e-05	0.000699	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—EGFR—ovarian cancer	4.39e-05	0.000699	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PPP1CC—ovarian cancer	4.34e-05	0.000691	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—BRIP1—ovarian cancer	4.34e-05	0.000691	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.24e-05	0.000674	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PIK3CD—ovarian cancer	4.24e-05	0.000674	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—PIK3CA—ovarian cancer	4.2e-05	0.000668	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—KRAS—ovarian cancer	4.15e-05	0.00066	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	4.09e-05	0.000651	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PPP1CC—ovarian cancer	3.96e-05	0.00063	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—BRIP1—ovarian cancer	3.96e-05	0.00063	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—CAV1—ovarian cancer	3.87e-05	0.000616	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	3.87e-05	0.000616	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—YAP1—ovarian cancer	3.86e-05	0.000614	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—PIK3CA—ovarian cancer	3.81e-05	0.000606	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—ERBB2—ovarian cancer	3.74e-05	0.000595	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—MTOR—ovarian cancer	3.69e-05	0.000588	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PIK3CB—ovarian cancer	3.69e-05	0.000588	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	3.68e-05	0.000586	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CXCL8—ovarian cancer	3.55e-05	0.000565	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—PIK3CG—ovarian cancer	3.53e-05	0.000562	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.53e-05	0.000561	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—HRAS—ovarian cancer	3.53e-05	0.000561	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CDKN1B—ovarian cancer	3.47e-05	0.000551	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—AKT1—ovarian cancer	3.43e-05	0.000546	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CASP3—ovarian cancer	3.4e-05	0.00054	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—IL2—ovarian cancer	3.39e-05	0.00054	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—IL6—ovarian cancer	3.37e-05	0.000537	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CCND1—ovarian cancer	3.31e-05	0.000526	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CTNNB1—ovarian cancer	3.27e-05	0.000521	CbGpPWpGaD
Prasugrel—ALB—Metabolism—YAP1—ovarian cancer	3.25e-05	0.000517	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.21e-05	0.000511	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—MMP9—ovarian cancer	3.21e-05	0.000511	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	3.2e-05	0.000509	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PTEN—ovarian cancer	3.19e-05	0.000508	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.17e-05	0.000504	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—FASN—ovarian cancer	3.14e-05	0.0005	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—AKT1—ovarian cancer	3.11e-05	0.000495	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—PIK3CD—ovarian cancer	3.1e-05	0.000494	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—SLC5A5—ovarian cancer	3.09e-05	0.000492	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—CYTB—ovarian cancer	2.99e-05	0.000476	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—SLC2A1—ovarian cancer	2.99e-05	0.000475	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—YAP1—ovarian cancer	2.91e-05	0.000464	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.89e-05	0.000459	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.88e-05	0.000459	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—VEGFA—ovarian cancer	2.88e-05	0.000459	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—CYP1B1—ovarian cancer	2.86e-05	0.000456	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—STAT3—ovarian cancer	2.85e-05	0.000454	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—NRAS—ovarian cancer	2.85e-05	0.000453	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.82e-05	0.000449	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—MAPK3—ovarian cancer	2.73e-05	0.000434	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—PIK3CB—ovarian cancer	2.7e-05	0.00043	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—YAP1—ovarian cancer	2.66e-05	0.000423	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—MYC—ovarian cancer	2.65e-05	0.000422	CbGpPWpGaD
Prasugrel—ALB—Metabolism—FASN—ovarian cancer	2.65e-05	0.000421	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.63e-05	0.000418	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PPP1CC—ovarian cancer	2.61e-05	0.000416	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—BRIP1—ovarian cancer	2.61e-05	0.000416	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	2.61e-05	0.000416	CbGpPWpGaD
Prasugrel—ALB—Metabolism—SLC5A5—ovarian cancer	2.6e-05	0.000414	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—MAPK1—ovarian cancer	2.59e-05	0.000413	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—EGFR—ovarian cancer	2.59e-05	0.000413	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PPP2R1A—ovarian cancer	2.54e-05	0.000404	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.53e-05	0.000403	CbGpPWpGaD
Prasugrel—ALB—Metabolism—SLC2A1—ovarian cancer	2.51e-05	0.0004	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—IL2—ovarian cancer	2.48e-05	0.000395	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.46e-05	0.000392	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—KRAS—ovarian cancer	2.45e-05	0.00039	CbGpPWpGaD
Prasugrel—ALB—Metabolism—CYP1B1—ovarian cancer	2.41e-05	0.000384	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—FASN—ovarian cancer	2.38e-05	0.000378	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—ABCB1—ovarian cancer	2.36e-05	0.000375	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—SLC5A5—ovarian cancer	2.34e-05	0.000372	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—TYMS—ovarian cancer	2.32e-05	0.000368	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.31e-05	0.000368	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—SLC2A1—ovarian cancer	2.26e-05	0.000359	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PIK3CA—ovarian cancer	2.25e-05	0.000358	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.21e-05	0.000352	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—TP53—ovarian cancer	2.18e-05	0.000347	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—FASN—ovarian cancer	2.17e-05	0.000345	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—CYP1B1—ovarian cancer	2.16e-05	0.000344	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PPP2R1A—ovarian cancer	2.14e-05	0.00034	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—SLC5A5—ovarian cancer	2.13e-05	0.000339	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.13e-05	0.000338	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—VEGFA—ovarian cancer	2.11e-05	0.000336	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—NRAS—ovarian cancer	2.08e-05	0.000332	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—HRAS—ovarian cancer	2.08e-05	0.000331	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—SLC2A1—ovarian cancer	2.06e-05	0.000327	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.01e-05	0.000321	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—MAPK3—ovarian cancer	2e-05	0.000318	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—IL6—ovarian cancer	1.99e-05	0.000317	CbGpPWpGaD
Prasugrel—ALB—Metabolism—ABCB1—ovarian cancer	1.98e-05	0.000316	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—CYP1B1—ovarian cancer	1.97e-05	0.000314	CbGpPWpGaD
Prasugrel—ALB—Metabolism—TYMS—ovarian cancer	1.95e-05	0.00031	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	1.92e-05	0.000305	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.91e-05	0.000304	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—MAPK1—ovarian cancer	1.9e-05	0.000302	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—CAV1—ovarian cancer	1.87e-05	0.000297	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—AKT1—ovarian cancer	1.84e-05	0.000293	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—KRAS—ovarian cancer	1.79e-05	0.000285	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—ABCB1—ovarian cancer	1.78e-05	0.000284	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—YAP1—ovarian cancer	1.75e-05	0.000279	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—TYMS—ovarian cancer	1.75e-05	0.000278	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	1.75e-05	0.000278	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.74e-05	0.000277	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PIK3CG—ovarian cancer	1.7e-05	0.00027	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—PIK3CA—ovarian cancer	1.65e-05	0.000262	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—ABCB1—ovarian cancer	1.62e-05	0.000259	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—TYMS—ovarian cancer	1.6e-05	0.000254	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—TP53—ovarian cancer	1.59e-05	0.000254	CbGpPWpGaD
Prasugrel—ALB—Metabolism—CAV1—ovarian cancer	1.57e-05	0.00025	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—HRAS—ovarian cancer	1.52e-05	0.000243	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.5e-05	0.000239	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PIK3CD—ovarian cancer	1.49e-05	0.000238	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PIK3CG—ovarian cancer	1.43e-05	0.000228	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—FASN—ovarian cancer	1.43e-05	0.000227	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—CAV1—ovarian cancer	1.41e-05	0.000224	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.4e-05	0.000224	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.36e-05	0.000216	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.35e-05	0.000214	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—AKT1—ovarian cancer	1.35e-05	0.000214	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PIK3CB—ovarian cancer	1.3e-05	0.000207	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.3e-05	0.000207	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—CAV1—ovarian cancer	1.29e-05	0.000205	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PIK3CG—ovarian cancer	1.28e-05	0.000204	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PIK3CD—ovarian cancer	1.26e-05	0.0002	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.23e-05	0.000195	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.17e-05	0.000186	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.15e-05	0.000184	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PIK3CD—ovarian cancer	1.13e-05	0.00018	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PTEN—ovarian cancer	1.13e-05	0.000179	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PIK3CB—ovarian cancer	1.1e-05	0.000174	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.07e-05	0.00017	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—TYMS—ovarian cancer	1.05e-05	0.000167	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.03e-05	0.000164	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PIK3CB—ovarian cancer	9.84e-06	0.000157	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PTEN—ovarian cancer	9.47e-06	0.000151	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PIK3CB—ovarian cancer	8.97e-06	0.000143	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PTEN—ovarian cancer	8.5e-06	0.000135	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—CAV1—ovarian cancer	8.48e-06	0.000135	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PIK3CA—ovarian cancer	7.94e-06	0.000126	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PTEN—ovarian cancer	7.75e-06	0.000123	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PIK3CG—ovarian cancer	7.72e-06	0.000123	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PIK3CD—ovarian cancer	6.79e-06	0.000108	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PIK3CA—ovarian cancer	6.68e-06	0.000106	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—AKT1—ovarian cancer	6.48e-06	0.000103	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PIK3CA—ovarian cancer	6e-06	9.55e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PIK3CB—ovarian cancer	5.92e-06	9.42e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PIK3CA—ovarian cancer	5.47e-06	8.7e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—AKT1—ovarian cancer	5.46e-06	8.69e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PTEN—ovarian cancer	5.11e-06	8.14e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—AKT1—ovarian cancer	4.9e-06	7.8e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—AKT1—ovarian cancer	4.47e-06	7.11e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PIK3CA—ovarian cancer	3.61e-06	5.74e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—AKT1—ovarian cancer	2.95e-06	4.69e-05	CbGpPWpGaD
